Amicus Therapeutics to Participate in BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference

CRANBURY, N.J., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in two upcoming conferences in February.

15th Annual BIO CEO & Investor Conference in New York, NY

Mr. Crowley will participate in a panel, "Orphan Drugs: Making Rare Diseases Rarer," to be held during the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 9:00 a.m. ET in New York, NY. More information about this panel can be found at

Leerink Swann Global Healthcare Conference

Mr. Crowley will present a corporate overview during the Leerink Swann Global Healthcare Conference 2013 in New York, NY on Wednesday, February 13, 2013 at 12:00 p.m. ET. A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus' late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.


CONTACT: Amicus Therapeutics Sara Pellegrino (609) 662-5044 spellegrino@amicusrx.comSource:Amicus Therapeutics, Inc.